HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer
Our findings encourage the exploration of the role of HDAC6 as a prognostic factor and the combinatorial use of HDAC6 selective inhibitors combined with trastuzumab in HER2+ BC, in particular for those patients experiencing drug resistance.
Authors
- Michela Cortesi (ORCID: https://orcid.org/0000-0001-6869-000X)
- Francesca Pirini (ORCID: https://orcid.org/0000-0002-7629-2439)
- Davide Angeli (ORCID: https://orcid.org/0000-0002-8855-0829)
- Elisabetta Petracci (ORCID: https://orcid.org/0000-0001-9456-3514)
- Roberta Maltoni (ORCID: https://orcid.org/0000-0003-0366-792X)
- Sara Bravaccini (ORCID: https://orcid.org/0000-0002-0075-8538)
- Andrea Rocca (ORCID: https://orcid.org/0000-0003-4613-8884)
- Michela Palleschi (ORCID: https://orcid.org/0000-0003-2623-4705)
- Paola Possanzini (ORCID: https://orcid.org/0000-0001-8415-1137)
- William Balzi (ORCID: https://orcid.org/0000-0002-6836-1422)
- Paola Ulivi (ORCID: https://orcid.org/0000-0002-4334-9662)
- Michele Zanoni (ORCID: https://orcid.org/0000-0003-1826-9430)
- Maria Maddalena Tumedei (ORCID: https://orcid.org/0000-0003-3105-9796)
- Giovanni Martinelli (ORCID: https://orcid.org/0000-0002-1025-4210)
- Sara Ravaioli (ORCID: https://orcid.org/0000-0002-9395-6452)
Institutions
- University of Trieste (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Ospedale G.B. Morgagni - L.Pierantoni (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-06
- DOI
- https://doi.org/10.3390/cancers16223752
- Citations
- 1
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.23